Replies to post #216234 on Biotech Values

[DewDiligence]

(ADXS)—75% of hypermutated CRC cases have MSI-high (according to the article you posted), but MSI-high CRC is excluded from the (planned) phase-1 trials of ADXS-NEO:

https://ir.advaxis.com/press-releases/detail/1280/advaxis-reports-business-update-and-third-quarter-2017

The initial tumor types for ADXS-NEO are metastatic microsatellite stable colon, head and neck, and non-small cell lung cancers.

Emphasis added.